This is a working overview of WADA, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-10 and is reviewed periodically as new material appears.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
== Administration of ACAM2000 == The ACAM2000 vaccine is produced from the vaccinia virus, which is sufficiently closely related to smallpox to provide immunity, but the ACAM2000 vaccine cannot cause smallpox because it does not contain the smallpox virus. Other vaccines containing live viruses include measles, mumps, rubella, polio and chickenpox. The vaccine is administered using a bifurcated stainless steel needle. The needle is dipped into the vaccine solution and used to prick the skin several times in the upper arm. The vaccinia virus will begin to grow at the injection site. It will cause a localized infection, with a red itchy sore produced at the vaccination site within three to four days. If the infection occurs, that is an indication that the vaccine was successful. Ultimately, the sore turns into a blister and then dries up. A scab forms and then falls off in the third week, leaving a small scar behind.
=== Initial zone: nucleation and growth mechanisms === Although the ability of ice to reject suspended particles in the growth process has long been known, the mechanism remains the subject of some discussion. It was believed initially that during the moments immediately following the nucleation of the ice crystals, particles are rejected from the growing planar ice front, leading to the formation of a constitutionally super-cooled zone directly ahead of the growing ice. This unstable region eventually results in perturbations, breaking the planar front into a columnar ice front, a phenomenon better known as a Mullins-Serkerka instability. After the breakdown, the ice crystals grow along the temperature gradient, pushing ceramic particles from the liquid phase aside so that they accumulate between the growing ice crystals. However, recent in-situ X-ray radiography of directionally frozen alumina suspensions reveal a different mechanism.
== Ecology == In its native habitat Vanilla planifolia depends on one or more pollinators. Several species of bee have been proposed including Euglossa species, Eulaema cingulata, Eulaema polychroma, Eulaema meriana, and Melipona beecheii for pollination. However, no definitive observation of pollination is recorded and the size of M. beecheii in particular make it unlikely to be a pollinator of this species of orchid, though unpublished observations suggest that Euglossa (reported as E. viridissima, but this species has historically been confused with other Euglossa species) might be capable of completing pollination. Attempts to document the visitation of V. planifolia in the Yucatán peninsula of Mexico failed to record any visitation by any stingless bees or orchid bees (including Melipona, Eulaema, and Euglossa), leaving the identity of its natural pollinators as yet unresolved. Though the seeds of Vanilla planifolia are very small, they are relatively large for an orchid and are not dispersed by the wind. Instead they spread through the rainforest habitat by many different animals. Male orchid bees in the tribe Euglossini in the genera Euglossa and Eulaema exhibit fragrance-collecting behavior with the fruits. Specific species observed removing seeds as part of this behavior include Euglossa bursigera, Euglossa ignita, Euglossa tridentata, and Eulaema cingulata. Conversely female stingless bees remove the pulp of the fruit in a behavior consistent with nest-building activities. The two species observed distributing V.
== Clinical significance == Truncation mutations in MYBPC3 stand as the primary cause of hypertrophic cardiomyopathy (HCM). To date, roughly 350 mutations in MYBPC3 have been identified, and in large part, the mutations result in protein truncation, shifts in reading frames, and premature termination codons. Genetic studies have revealed significant overlap between genotypes and phenotypes as MYBPC3 mutations can lead to various forms of cardiomyopathies, such as dilated cardiomyopathy and left ventricular noncompaction cardiomyopathy. In patients with isolated or familial cases of dilated cardiomyopathy, MYBPC3 mutations represented the second highest number of known mutations. Furthermore, a 25-bp intronic MYBPC3 deletion leading to protein truncation is present in 4% of the population in South India and is associated with a higher risk to develop heart failure. Founder MYBPC3 mutations have been reported in Iceland, Italy, The Netherlands, Japan, France and Finland, where they represent a large percentage of cases with hypertrophic cardiomyopathy. All of them are truncating mutations, resulting in a shorter protein, lacking the regulatory phosphorylatable M motif and/or major binding domains to other sarcomeric proteins. A body of evidence indicates that patients with more than one mutation often develop a more severe phenotype, and a significant fraction of childhood-onset hypertrophic cardiomyopathy (14%) is caused by compound genetic variants. This suggests that a gene-dosage effect might be responsible for manifestations at a younger age.
Sources: en.wikipedia.org
=== Religious criticisms === Many Christians criticized the war. Robert McElroy, a Cardinal for the Catholic Church, called for an end for the war, and Leo XIV, the current Pope echoed this statement. Hegseth in response attempted to appeal to earlier times in the Catholic Church, particularly the era of the Crusades. However, the Crusaders were not only anti-Muslim but also anti-Jewish.
Intestinal desmosis is a medical condition implicated in gut motility disorder and chronic constipation. Desmosis can be observed as the absence of the tendinous plexus layer and connective tissue fibers.
A sickle cell crisis occurs when red blood cells switch from the normal saucer-like shape to a sickle-like shape, which can obstruct small blood vessels; an attack can be set off by temperature changes, stress, dehydration, and high altitude. A person with a single abnormal gene does not usually have symptoms and is said to have sickle cell trait; these people are also referred to as carriers. Diagnosis is by a blood test. Some countries test all babies at birth for the disease. Diagnosis of the unborn foetus is also possible during pregnancy. The care of people with sickle cell disease may include infection prevention with vaccination and antibiotics, high fluid intake, folic acid supplementation, and pain medication. Other measures may include blood transfusion and the medication hydroxycarbamide (hydroxyurea). In 2023, new gene therapies were approved involving the genetic modification and replacement of blood forming stem cells in the bone marrow. As of 2021, sickle cell disease is estimated to affect about 7.7 million people worldwide, directly causing an estimated 34,000 annual deaths and a contributory factor to a further 376,000 deaths. About 80% of sickle cell disease cases are believed to occur in sub-Saharan Africa. It also occurs to a lesser degree among people in parts of India, Southern Europe, West Asia, North Africa and among people of African origin (sub-Saharan) living in other parts of the world. The condition was first described in the medical literature by American physician James B. Herrick in 1910.
Ross (1971), historian and professor at University of Southern California, 2018 Pulitzer Prize for History finalist Roy Rosenzweig (1971), historian and director of the Center for History and New Media at George Mason University Scott Atran (1972), anthropologist; director at Centre National de la Recherche Scientifique and presidential scholar at John Jay College of Criminal Justice Joel Black (1972), literature and film scholar Michael Gerrard (1972), professor at Columbia Law School Jerome Groopman (1972), Harvard Medical School professor and medical writer for The New Yorker Robert Hymes (1972), professor of Chinese history at Columbia University, winner of two Joseph Levenson Book Prizes George Klosko (1972), professor of philosophy at the University of Virginia Mark J. Roe (1972), professor at Harvard Law School John Servos (1972), professor and historian of science; president of the History of Science Society David Stern (1972), professor of Hebrew literature at Harvard University Tom R. Tyler (1972), professor of psychology at Yale Law School Harold Aram Veeser (1972), professor at City College of New York, known for contribution to new historicism Sean Wilentz (1972), historian and winner of the Bancroft Prize; chair of American Studies at Princeton University Angelo Falcón (1973), political scientist, president and founder of the National Institute for Latino Policy Steven Messner (1973), sociologist, professor of the University at Albany, SUNY, former president of the American Society of Criminology William C.
Modern frozen section method. Frozen section histology does not give the added margin of safety by the cytotoxic Mohs paste, originally used by Mohs. This paste might have destroyed any residual cancer cells not detected by the pathologist. Missing epidermal margins. Ideally, the Mohs section should include 100% of the epidermal margin, but greater than 95% is often accepted. Vigorous scrubbing, poorly controlled initial curettage, poor tissue health, technician's error, and surgeon's error can introduce areas missing epithelial margin. Some surgeons consider 70% epithelial margin acceptable, while others suggest 100% margin. In the ideal situation, 100% of the epithelial margin should be available to be reviewed on serial sectioning of the Mohs specimen. Misreading of the pathology slide. It is difficult to differentiate between a small island of basal-cell carcinoma and a hair follicle structure. Many Mohs surgeons limit their tissue processing to include only 2 sections of tissue. This severely hampers their ability to determine if a structure is a hair follicle or a carcinoma. Two histologic sections can not fully distinguish these two nearly identical structures, and can lead to either "false negative" or "false positive" errors by either calling a section clear of tumor, or calling a section positive for tumor, respectively. Serial sectioning of the tumor is preferred by other surgeons.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.